API5 confers cancer stem cell-like properties through the FGF2-NANOG axis

作者：Song K H; Cho H; Kim S; Lee H J; Oh S J; Woo S R; Hong S O; Jang H S; Noh K H; Choi C H; Chung J Y; Hewitt S M; Kim J H; Son M; Kim S H; Lee B I; Park H C; Bae Y K^*; Kim T W^*

来源：Oncogenesis, 2017, 6(1): e285.

DOI：10.1038/oncsis.2016.87

Immune selection drives the evolution of tumor cells toward an immune-resistant and cancer stem cell (CSC)-like phenotype. We reported that apoptosis inhibitor-5 (API5) acts as an immune escape factor, which has a significant role in controlling immune resistance to antigen-specific T cells, but its functional association with CSC-like properties remains largely unknown. In this study, we demonstrated for the first time that API5 confers CSC-like properties, including NANOG expression, the frequency of CD44-positive cells and sphere-forming capacity. Critically, these CSC-like properties mediated by API5 are dependent on FGFR1 signaling, which is triggered by E2F1-dependent FGF2 expression. Furthermore, we uncovered the FGF2-NANOG molecular axis as a downstream component of API5 signaling that is conserved in cervical cancer patients. Finally, we found that the blockade of FGFR signaling is an effective strategy to control API5(high) human cancer. Thus, our findings reveal a crucial role of API5 in linking immune resistance and CSC-like properties, and provide the rationale for its therapeutic application for the treatment of API5(+) refractory tumors.

• 出版日期2017-1
• 单位西北大学; NIH